That's simple.

Here's the official Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine vs Placebo

Among 44,486 evaluable participants, irrespective of prior SARS-CoV-2 infection, 81 COVID-19 cases were observed among vaccine and 873 among placebo recipients.

On p.12 of the Supplementary material is the table of fatalities.

Total 15 for BNT162b2 vs 14 for placebo

of those
COVID-19: 0 BNT162b2 vs 2 for placebo
COVID-19: pneumonia 1 for BNT162b2 vs 0 for placebo
Cardiac arrest: 4 for BNT162b2 vs 1 for placebo

but despite these, it seems there is no statistically significant effect on fatality either way

As for Adverse Events, after reading this:

Adverse event analyses during the blinded period are provided for 43,847 ≥16-year-olds . Reactogenicity events among participants not in the reactogenicity subset are reported as adverse events, resulting in imbalances in adverse events (30% vs 14%), related adverse events (24% vs 6%), and severe adverse events (1.2% vs 0.7%) between BNT162b2 and placebo groups. Decreased appetite, lethargy, asthenia, malaise, night sweats, and hyperhidrosis were new adverse events attributable to BNT162b2 not previously identified in earlier reports.

I wouldn't even want the placebo !

But then they contacted all the placebo people and offered them the Vx. 95% of the placebo recipients in the UK then accepted the offer. I imagine roughly the same amount accepted in other regions - they went for the Vx after all.

So the placebo group has been destroyed so there will be no 1 year study, or 3 year study, 5 year, 10 year etc.